Reading ABEO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ABEO free→Reading ABEO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ABEO free→NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral, and management's recent track record has been steady. The company was unprofitable over the past year, so its earnings quality can't be assessed. Risk is elevated, and the sector backdrop is a headwind, with ABEO trading below typical compared to sector peers. Peer multiples imply a price about 65% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples but recent financials are weak. If ABEO cuts guidance on the next call, that's a meaningful negative. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 3 valuation methods, at three horizons. Current price $5.53. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $5.53 ABEO trades at 6× p/e, below its 17× p/e peer median. Our $16 fair value sits above the price; medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 65% below a flat-multiple fair value, below our forecast of about 100%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 1.02x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
6 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.29 → $-0.23 (+19.6% / 30d). 0 raised, 3 cut, 3 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 100% of analysts rate Buy.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$197.
How much price usually moves either way.
On a bad day, this stock has moved -$483.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,232.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Improving net income is crucial for Abeona to reach profitability in 1H 2026. Investors will look for signs of progress.
Confirms:Q2 2026 net income improves to less than -$10M.
Disproves:Q2 2026 net income remains worse than -$15M.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for ABEO yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Director — Michael Amoroso: Mr. Amoroso resigned from the Board of Directors for personal reasons.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
ABEO Abeona Therapeutics, Inc. | Below typical Show detailsSector percentile: 30 of 100 | inexpensive | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 78 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Management aims to achieve profitability in the first half of 2026.
Management plans to launch ZEVASKYN in the third quarter of 2025.
Management expects to fund operations for over two years without ZEVASKYN revenue.
Why it matters: The recent change in officers may change Abeona's strategy. Investors need to watch for news.
Confirms one read:Abeona announces a new executive with a strong track record in biotech.
Confirms the other:No new executives have been hired. There are no updates to the strategy.
Why it matters: Monitoring cash burn is vital for Abeona to fund operations for over two years. It indicates financial health.
Confirms:Q2 2026 cash burn is less than -$15M.
Disproves:Q2 2026 cash burn exceeds -$20M.
Why it matters: Updates on ZEVASKYN's launch will show if Abeona is on track to meet its 3Q 2025 goal. This is key for revenue growth.
Confirms:Abeona released a press statement. It confirms ZEVASKYN's launch date and first sales numbers.
Disproves:No updates on ZEVASKYN's launch by the end of Q3 2026.
Results of Operations and Financial Condition. On May 13, 2026, Abeona Therapeutics Inc. (the “Company”) issued a press release regarding its financial results for the quarter ended March 31, 2026. On the same date, the Company posted on its investor relations website, located at investors.abeonatherapeutics.com, a presentation that will be used by management during the Company’s earnings conference call (the “Earnings Presentation”). A copy of the press release and the Earnings Presentation…
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On April 1, 2026, the Board of Directors (the “Board”) of Abeona Therapeutics Inc. (the “Company”), acting upon the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Board from nine to ten members and appointed Keith A. Goldan as a member of the Board of the Company as a Class 1 director. Mr. Goldan will serve on the Board for a term expiring at t…
of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.